Media Outlets Should Cover This Historic HIV/AIDS Development
The Centers for Disease Control and Prevention’s (CDC) ringing endorsement last week of Truvada, the “miracle drug” that blocks HIV infection, presents news outlets with a prime opportunity to cover an historic development in the three-decade struggle against HIV/AIDS. So far, however, media organizations have largely ignored the story.
Truvada is a 10-year-old pre-exposure prophylaxis (PrEP) treatment combining two different antiviral drugs. Taken daily, it prevents infection of HIV. Even though the Food and Drug Administration (FDA) approved the drug back in July 2012, it hasn’t exactly caught on; a September 2013 report by Gilead Sciences found that only 1,774 people had filled Truvada prescriptions from January 2011 through March 2013. Nearly half of users were women, even though gay men are the demographic group most at risk for HIV/AIDS.
Part of the reason Truvada has been slow to gain steam is, undoubtedly, the stigma attached to those who use it. Gay men who use the drug have been derided as “Truvada Whores,” a term many users have sought to reclaim. Some HIV/AIDS advocates, including Michael Weinstein of the AIDS Healthcare Foundation, have cast doubt on Truvada’s effectiveness, noting that it won’t block infection unless users strictly adhere to taking it daily.
But advocates who hail Truvada Continue here